Conferences - Results from #320

Viewing 321-340 of 11869 articles

ESMO 2024: The Role of Urologist in Bladder Preservation Strategies

ESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data at the 2024 ESMO Congress

ESMO 2024: Clinical responders: Option of Chemoradiation?

ESMO 2024: Biomarkers and Prediction of Clinical Complete Response in Bladder Cancer

ESMO 2024: Will Theranostics Become Standard of Care?

ESMO 2024: Could Optimal Systemic Therapy Be Adequate Without Locoregional Therapy?

ESMO 2024: Invited Discussant: Optimizing Post-IO Therapy in Clear Cell RCC and Expanding Options for Non-Clear Cell RCC

ESMO 2024: Invited Discussant: Moving the Needle: Novel Targets and Refined Approaches in Genitourinary Cancers

ESMO 2024: NKT2152, a Novel Oral HIF-2α Inhibitor, in Participants with Previously Treated Advanced Clear Cell RCC: Preliminary Results of a Phase 1/2 Study

ESMO 2024: BL-B01D1-201: BL-B01D1, an EGFR x HER3 Bispecific Antibody-drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

ESMO 2024: Are Cytotoxics Still the Next Option?

ESMO 2024: Prospective Randomized Phase II Trial of Ipilimumab + Nivolumab Versus Standard of Care in Non-Clear Cell RCC: Results of the SUNNIFORECAST Trial

ESMO 2024: Final Analysis of the Phase 3 LITESPARK-005 Study of Belzutifan Versus Everolimus in Participants with Previously Treated Advanced Clear Cell RCC

ESMO 2024: Tivozanib–Nivolumab vs Tivozanib Monotherapy in Patients with RCC Following 1 or 2 Prior Therapies including an Immune Checkpoint Inhibitor – Results of the Phase III TiNivo-2 Study

Astellas Presents Scientific Progress in Advanced and Hard-to-Treat Cancers at ESMO 2024

AVEO Oncology, an LG Chem company, Announces Acceptance of Late-Breaking Oral Presentation of TiNivo-2 Results at ESMO 2024

ESMO 2024: Bayer to Present New Prostate Cancer Data and Continued Oncology Portfolio Research at ESMO 2024

Lantheus to Present Additional Clinical Data from Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024

WCET 2024: Robot Radical Prostatectomy: How to Achieve Better Continence Outcomes

WCET 2024: Xi and SP Nephroureterectomy and Bladder Cuff

12
13
14
15
16
17
18
19
20
21